Tag Archives: VC

Bubbleology and Biotech’s Bull Run

Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since the beginning of 2012 the Nasdaq Biotechnology…

Share

Biotech Fundraising Dips in Q112, But No Need to Panic

I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year. That’s good news, especially given…

Share

Conference Etiquette – is There an App for That?

There’s a new contagious condition circulating that has even infected the biotech sector: e-Distraction, with bad manner side effects of indecorum, insensitivity and more. The wealthy are often regarded as egocentric and out of touch with reality by the 99…

Share

Biotech Series A Funding Up in 2011 . . . But There’s a Catch

Despite the fact that private biotechs raised just $1.76 billion in the first five months of 2011 – putting this year on pace to be not only worse than last year, but worse than the dreaded low of 2008 –…

Share